Continuing the race adjustment factors maintains health care disparities, the authors noted.
Clinicians should stop using the race adjustment factor in pulmonary function testing (PFT), according to a recent entry in the Things We Do for No Reason series in the Journal of Hospital Medicine.
The authors wrote that adjusting spirometry values stems from old studies about differences in lung function among races, which were then applied to testing. As a result, lung volume reference values for Black patients are 10% to 15% lower than values for White patients.
There are 3 reasons why the race adjustment factor in PFT is injurious to patients, the authors wrote:
“The medical community should follow the lead of other equations, like estimated glomerular filtration rate and the vaginal birth after cesarean calculator, which have successfully removed race factors,” the authors wrote.
Continuing race adjustment maintains health care disparities, they said, and any concerns about the possibility of overdiagnosing disease must be outweighed by the harm that comes from underdiagnosing it.
They called upon clinicians to:
“As a profession, we must practice race-conscious medicine that values individualized care, recognizes the contributions of structural racism and social determinants in patient health, and standardize care when possible, based on objective metrics,” they wrote.
The Things We Do for No Reason series is inspired by the Choosing Wisely program, which seeks to promote high-value care by educating clinicians and the public about low-value care.
Reference
Beaverson S, Ngo VM, Pahuja M, Dow A, Nana-Sinkham P, Schefft M. Things We Do for No Reason: race adjustments in calculating lung function from spirometry measurements. J Hosp Med. Published online October 7, 2022. 10.1002/jhm.12974
Study Highlights Significant Increases in Utilization, Spending on DMD Drugs in Medicaid
May 17th 2024The findings add to recent research on the growing utilization, expenditure, and prices of Duchenne muscular dystrophy (DMD) therapies in the current landscape, an area health care policy could potentially address.
Read More
Frameworks for Advancing Health Equity: Urban Health Outreach
May 9th 2024In the series debut episode of "Frameworks for Advancing Health Equity," Mary Sligh, CRNP, and Chelsea Chappars, of Allegheny Health Network, explain how the Urban Health Outreach program aims to improve health equity for individuals experiencing homelessness.
Listen
Perioperative Nivolumab Boosts NSCLC Survival: CheckMate 77T Trial
May 16th 2024This interim analysis of the CheckMate 77T trial, outcomes were compared between adult patients receiving neoadjuvant nivolumab plus chemotherapy or neoadjuvant chemotherapy plus placebo for resectable non–small cell lung cancer (NSCLC).
Read More
Study Highlights Significant Increases in Utilization, Spending on DMD Drugs in Medicaid
May 17th 2024The findings add to recent research on the growing utilization, expenditure, and prices of Duchenne muscular dystrophy (DMD) therapies in the current landscape, an area health care policy could potentially address.
Read More
Frameworks for Advancing Health Equity: Urban Health Outreach
May 9th 2024In the series debut episode of "Frameworks for Advancing Health Equity," Mary Sligh, CRNP, and Chelsea Chappars, of Allegheny Health Network, explain how the Urban Health Outreach program aims to improve health equity for individuals experiencing homelessness.
Listen
Perioperative Nivolumab Boosts NSCLC Survival: CheckMate 77T Trial
May 16th 2024This interim analysis of the CheckMate 77T trial, outcomes were compared between adult patients receiving neoadjuvant nivolumab plus chemotherapy or neoadjuvant chemotherapy plus placebo for resectable non–small cell lung cancer (NSCLC).
Read More
2 Commerce Drive
Cranbury, NJ 08512